β-secretase (BACE) and GSK-3 mRNA levels in Alzheimer's disease

被引：53

作者：

Preece, P

Virley, DJ

Costandi, M

Coombes, R

Moss, SJ

Mudge, AW

Jazin, E

Cairns, NJ

机构：

[1] Quantuum, Dept Neurol, La Coruna 15177, Galicia, Spain

[2] Glaxo SmithKline Pharmaceut, Dept Neurosci, Harlow CM19 5AW, Essex, England

[3] Guys Hosp, Kings Coll London, MRC Ctr Dev Neurobiol, London SE1 1UL, England

[4] UCL, MRC Lab Mol & Cellular Biol, London WC1E 6BT, England

[5] Uppsala Univ, Rudbeck Lab, Dept Med Genet, S-75185 Uppsala, Sweden

[6] Uppsala Univ, Rudbeck Lab, Dept Pathol, S-75185 Uppsala, Sweden

[7] Univ Penn, Sch Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA

来源：

MOLECULAR BRAIN RESEARCH | 2003年 / 116卷 / 1-2期

关键词：

Alzheimer's disease; human brain; mRNA; quantification; TaqMan; BACE; GSK-3;

D O I：

10.1016/S0169-328X(03)00233-X

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

beta-Secretase (BACE) and glycogen synthase kinase (GSK 3) are two enzymes thought to play a role in Alzheimer's disease. We extracted mRNA from 90 Alzheimer and 81 control brains. Levels of mRNA were quantified for BACE and GSK 3 with TaqMan(TM) real-time RT-PCR. We found no change in the Alzheimer's disease brains relative to controls for either the BACE or the GSK 3alpha mRNA levels. (C) 2003 Elsevier B.V. All rights reserved.

引用

页码：155 / 158

页数：4

共 50 条

[1] Multitarget Drug Discovery for Alzheimer's Disease: Triazinones as BACE-1 and GSK-3β Inhibitors
Prati, Federica
De Simone, Angela
Bisignano, Paola
Armirotti, Andrea
Summa, Maria
Pizzirani, Daniela
Scarpelli, Rita
Perez, Daniel I.
Andrisano, Vincenza
Perez-Castillo, Ana
Monti, Barbara
Massenzio, Francesca
Polito, Letizia
Racchi, Marco
Favia, Angelo D.
Bottegoni, Giovanni
Martinez, Ana
Bolognesi, Maria Laura
Cavalli, Andrea
[J]. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2015, 54 (05) : 1578 - 1582
[2] Dual BACE-1/GSK-3β Inhibitors to Combat Alzheimer's Disease A Focused Review
Rampa, Angela
Gobbi, Silvia
Di Martino, Rita Maria Concetta
Belluti, Federica
Bisi, Alessandra
[J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2017, 17 (31) : 3361 - 3369
[3] GSK-3 is essential in the pathogenesis of Alzheimer's disease
Takashima, Akihiko
[J]. JOURNAL OF ALZHEIMERS DISEASE, 2006, 9 : 309 - 317
[4] Role of GSK-3β in Alzheimer's disease pathology
Planel, E
Sun, XY
Takashima, A
[J]. DRUG DEVELOPMENT RESEARCH, 2002, 56 (03) : 491 - 510
[5] The β-Secretase BACE1 in Alzheimer's Disease
Hampel, Harald
Vassar, Robert
De Strooper, Bart
Hardy, John
Willem, Michael
Singh, Neeraj
Zhou, John
Yan, Riqiang
Vanmechelen, Eugeen
De Vos, Ann
Nistico, Robert
Corbo, Massimo
Imbimbo, Bruno Pietro
Streffer, Johannes
Voytyuk, Iryna
Timmers, Maarten
Monfared, Amir Abbas Tahami
Irizarry, Michael
Albala, Bruce
Koyama, Akihiko
Watanabe, Naoto
Kimura, Teiji
Yarenis, Lisa
Lista, Simone
Kramer, Lynn
Vergallo, Andrea
[J]. BIOLOGICAL PSYCHIATRY, 2021, 89 (08) : 745 - 756
[6] β-Secretase (BACE) as a drug target for alzheimer's disease
Vassar, R
[J]. ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (12) : 1589 - 1602
[7] GSK-3 and Tau: A Key Duet in Alzheimer's Disease
Sayas, Carmen Laura
Avila, Jesus
[J]. CELLS, 2021, 10 (04)
[8] GSK-3 inhibitors and their potential in the treatment of Alzheimer's disease
Kypta, RM
[J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2005, 15 (10) : 1315 - 1331
[9] Towards the development of potential dual GSK-3β/BACE-1 inhibitors: a strategy to fight Alzheimer's disease
Martins, M.
Maia, M.
Gil-Martins, E.
Gales, L.
Remiao, F.
Pinto, M.
Silva, R.
Sousa, E.
[J]. TOXICOLOGY LETTERS, 2021, 350 : S110 - S111
[10] GSK-3β, a pivotal kinase in Alzheimer disease
Llorens-Martin, Maria
Jurado, Jeronimo
Hernandez, Felix
Avila, Jesus
[J]. FRONTIERS IN MOLECULAR NEUROSCIENCE, 2014, 7

← 1 2 3 4 5 →